Form 4: Tonix Pharmaceuticals Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director James Randolph Hunter Jr. was granted 22,700 stock options in Tonix Pharmaceuticals Holding Corp. as part of the 2026 Stock Incentive Plan.
Summary
- Director James Randolph Hunter Jr. received a grant of 22,700 stock options on May 12, 2026.
- The options have an exercise price of $13.28 per share.
- The grant is subject to a vesting schedule tied to the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting of Stockholders.
- The options expire on May 12, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future dilution of existing shareholders upon the exercise of these options.
Risks
- Market volatility affecting the value of the underlying common stock relative to the $13.28 exercise price.
Future Outlook
The options vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders, indicating a standard retention-based incentive structure.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term clinical and commercial milestones.
Comparison to Industry Standards
- The use of a one-year vesting period is consistent with standard corporate governance practices for non-employee director compensation in small-cap biotech firms.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of stock options under the 2026 Stock Incentive Plan. | 05/12/2026 | Standard alignment of director compensation with company performance. |
Stakeholder Impact
- Minor dilution impact for existing shareholders upon potential future exercise of options.
Next Steps
- Vesting of options on May 12, 2027, or the 2027 Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 05/12/2026 | Date of grant and earliest transaction. |
| 05/12/2027 | Vesting date for the stock options. |
| 05/14/2026 | Date of filing. |
| 05/12/2036 | Expiration date of the stock options. |
Keywords
Tonix Pharmaceuticals, TNXP, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.